After a productive JPM week including Biotech Showcase in San Francisco, Aagami has won its first new client of 2026, within few days. Client is ...
Published : 21 Jan 2026
Read MoreAagami has secured a contract extension from its publicly listed Japanese client to support US partnering for their patented, FDA-approved topical lid...
Published : 04 Dec 2025
Read MoreAagami has been granted a contract extension by its US-based client, who is working on a Phase 3 EPO asset designed to aid in resuscitation following ...
Published : 26 Nov 2025
Read MoreAn innovative ASX-Listed Pharma from Australia, with Marketed Povidone-Iodine Antiseptic Nasal Spray has appointed Aagami to help out-license the...
Published : 20 Oct 2025
Read MoreWe are pleased to announce that Aagami calendar of 2026 Partnering events is tentatively finalized. Various members of Aagami are expected ...
Published : 11 Sep 2025
Read MoreAagami met its past Belgian client during BIO 2025 in Boston. Thereafter, now we have received a new out-licensing assignment from Belgian client.&nbs...
Published : 01 Aug 2025
Read MoreAagami has received contract extension from its US based client owing to their experience with us and progress seen. The client’s Phase 2...
Published : 18 Jul 2025
Read MoreAagami Research Team (ART) has prepared a Business Research report , highlighting select cross border deals of Indian companies (Jan 2023 – Mar 2025...
Published : 23 Jun 2025
Read MoreAagami has received a new assignment from their publicly listed Japanese client, to help them out-license Topical Lidocaine Patch (Patented) for the U...
Published : 05 Jun 2025
Read MoreWe are glad to announce that Aagami has been appointed by a new client who are “Metastasis Specialists” uncoupling Metastasis and Proliferat...
Published : 29 May 2025
Read More